Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1

Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene NF1 and predisposes patients to developing nervous system tumors. Twenty percent of NF1 patients harbor nonsense mutations resulting in premature termination codons (PTCs). Nonsense suppression therapies can...

Descripción completa

Detalles Bibliográficos
Autores principales: Osum, Sara H., Oribamise, Eunice I., Corbière, Stanislas M.A.S., Taisto, Mandy, Jubenville, Tyler, Coutts, Alex, Kirstein, Mark N., Fisher, James, Moertel, Christopher, Du, Ming, Bedwell, David, Largaespada, David A., Watson, Adrienne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384610/
https://www.ncbi.nlm.nih.gov/pubmed/37520682
http://dx.doi.org/10.1016/j.omtn.2023.06.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384610/
https://www.ncbi.nlm.nih.gov/pubmed/37520682
http://dx.doi.org/10.1016/j.omtn.2023.06.018

Ejemplares similares